468 related articles for article (PubMed ID: 30538138)
21. Self-reported changes in the expanded disability status scale score in patients with multiple sclerosis after autologous stem cell transplants: real-world data from a single center.
Ruiz-Argüelles GJ; Olivares-Gazca JC; Olivares-Gazca M; Leon-Peña AA; Murrieta-Alvarez I; Cantero-Fortiz Y; Gomez-Cruz GB; Ruiz-Argüelles A; Priesca-Marin M; Ruiz-Delgado GJ
Clin Exp Immunol; 2019 Dec; 198(3):351-358. PubMed ID: 31394007
[TBL] [Abstract][Full Text] [Related]
22. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
Leuk Lymphoma; 2000 Mar; 37(1-2):115-23. PubMed ID: 10721775
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of autologous hematopoietic stem-cell transplantation following natalizumab discontinuation in aggressive multiple sclerosis.
Mariottini A; Innocenti C; Forci B; Magnani E; Mechi C; Barilaro A; Nistri R; Fani A; Saccardi R; Massacesi L; Repice AM
Eur J Neurol; 2019 Apr; 26(4):624-630. PubMed ID: 30414315
[TBL] [Abstract][Full Text] [Related]
24. Long-term results of autografting persons with multiple sclerosis are better in those not exposed to prior disease-modifying therapies.
Sánchez-Bonilla D; Robles-Nasta M; Gallardo-Pérez MM; Hernández-Flores EJ; Montes-Robles M; Pastelín-Martínez ML; Garcés-Eisele SJ; Olivares-Gazca JC; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Mult Scler Relat Disord; 2023 Jul; 75():104744. PubMed ID: 37178580
[TBL] [Abstract][Full Text] [Related]
25. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Burt RK; Balabanov R; Burman J; Sharrack B; Snowden JA; Oliveira MC; Fagius J; Rose J; Nelson F; Barreira AA; Carlson K; Han X; Moraes D; Morgan A; Quigley K; Yaung K; Buckley R; Alldredge C; Clendenan A; Calvario MA; Henry J; Jovanovic B; Helenowski IB
JAMA; 2019 Jan; 321(2):165-174. PubMed ID: 30644983
[TBL] [Abstract][Full Text] [Related]
26. Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis.
Mariottini A; Filippini S; Innocenti C; Forci B; Mechi C; Barilaro A; Fani A; Carlucci G; Saccardi R; Massacesi L; Repice AM
Mult Scler; 2021 Jan; 27(1):61-70. PubMed ID: 32008439
[TBL] [Abstract][Full Text] [Related]
27. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.
Kalincik T; Sharmin S; Roos I; Freedman MS; Atkins H; Burman J; Massey J; Sutton I; Withers B; Macdonell R; Grigg A; Torkildsen Ø; Bo L; Lehmann AK; Havrdova EK; Krasulova E; Trnený M; Kozak T; van der Walt A; Butzkueven H; McCombe P; Skibina O; Lechner-Scott J; Willekens B; Cartechini E; Ozakbas S; Alroughani R; Kuhle J; Patti F; Duquette P; Lugaresi A; Khoury SJ; Slee M; Turkoglu R; Hodgkinson S; John N; Maimone D; Sa MJ; van Pesch V; Gerlach O; Laureys G; Van Hijfte L; Karabudak R; Spitaleri D; Csepany T; Gouider R; Castillo-Triviño T; Taylor B; Sharrack B; Snowden JA; ; ; Mrabet S; Garber J; Sanchez-Menoyo JL; Aguera-Morales E; Blanco Y; Al-Asmi A; Weinstock-Guttman B; Fragoso Y; de Gans K; Kermode A;
JAMA Neurol; 2023 Jul; 80(7):702-713. PubMed ID: 37437240
[TBL] [Abstract][Full Text] [Related]
28. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
Muraro PA; Pasquini M; Atkins HL; Bowen JD; Farge D; Fassas A; Freedman MS; Georges GE; Gualandi F; Hamerschlak N; Havrdova E; Kimiskidis VK; Kozak T; Mancardi GL; Massacesi L; Moraes DA; Nash RA; Pavletic S; Ouyang J; Rovira M; Saiz A; Simoes B; Trnený M; Zhu L; Badoglio M; Zhong X; Sormani MP; Saccardi R;
JAMA Neurol; 2017 Apr; 74(4):459-469. PubMed ID: 28241268
[TBL] [Abstract][Full Text] [Related]
29. The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies.
Amoriello R; Greiff V; Aldinucci A; Bonechi E; Carnasciali A; Peruzzi B; Repice AM; Mariottini A; Saccardi R; Mazzanti B; Massacesi L; Ballerini C
Front Immunol; 2020; 11():559. PubMed ID: 32328061
[TBL] [Abstract][Full Text] [Related]
30. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.
Nash RA; Hutton GJ; Racke MK; Popat U; Devine SM; Steinmiller KC; Griffith LM; Muraro PA; Openshaw H; Sayre PH; Stuve O; Arnold DL; Wener MH; Georges GE; Wundes A; Kraft GH; Bowen JD
Neurology; 2017 Feb; 88(9):842-852. PubMed ID: 28148635
[TBL] [Abstract][Full Text] [Related]
31. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.
Decaudin D; Mounier N; Tilly H; Ribrag V; Ghesquières H; Bouabdallah K; Morschhauser F; Coiffier B; Le Gouill S; Bologna S; Delarue R; Huynh A; Bosly A; Brière J; Gisselbrecht C
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):212-8. PubMed ID: 21575926
[TBL] [Abstract][Full Text] [Related]
32. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Cashen AF; Fletcher T; Ceriotti C; Gao F; Ghobadi A; Vij R; Stockerl-Goldstein K; DiPersio J; Abboud C
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2155-2158. PubMed ID: 27575541
[TBL] [Abstract][Full Text] [Related]
33. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
[TBL] [Abstract][Full Text] [Related]
34. Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study.
Martín A; Caballero MD; Pérez-Simón JA; López-Holgado N; Mateos MV; Cañizo MC; Miguel JF
Bone Marrow Transplant; 2004 Oct; 34(8):675-82. PubMed ID: 15334049
[TBL] [Abstract][Full Text] [Related]
35. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis.
Abrahamsson SV; Angelini DF; Dubinsky AN; Morel E; Oh U; Jones JL; Carassiti D; Reynolds R; Salvetti M; Calabresi PA; Coles AJ; Battistini L; Martin R; Burt RK; Muraro PA
Brain; 2013 Sep; 136(Pt 9):2888-903. PubMed ID: 23864273
[TBL] [Abstract][Full Text] [Related]
36. Autologous hematopoietic stem cell transplantation (AHSCT) for aggressive multiple sclerosis - whom, when and how.
Szczechowski L; Śmiłowski M; Helbig G; Krawczyk-Kuliś M; Kyrcz-Krzemień S
Int J Neurosci; 2016 Oct; 126(10):867-71. PubMed ID: 26577419
[TBL] [Abstract][Full Text] [Related]
37. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
[TBL] [Abstract][Full Text] [Related]
38. Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas.
Sakellari I; Mallouri D; Batsis I; Apostolou C; Konstantinou V; Abela EM; Douka V; Marvaki A; Karypidis K; Iskas M; Baliakas P; Kaloyannidis P; Yannaki E; Sotiropoulos D; Kouvatseas G; Smias C; Anagnostopoulos A
Leuk Lymphoma; 2015; 56(11):3071-81. PubMed ID: 25760637
[TBL] [Abstract][Full Text] [Related]
39. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS.
Mancardi GL; Saccardi R; Filippi M; Gualandi F; Murialdo A; Inglese M; Marrosu MG; Meucci G; Massacesi L; Lugaresi A; Pagliai F; Sormani MP; Sardanelli F; Marmont A;
Neurology; 2001 Jul; 57(1):62-8. PubMed ID: 11445629
[TBL] [Abstract][Full Text] [Related]
40. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.
Vaivade A; Wiberg A; Khoonsari PE; Carlsson H; Herman S; Al-Grety A; Freyhult E; Olsson-Strömberg U; Burman J; Kultima K
Lipids Health Dis; 2023 Jul; 22(1):97. PubMed ID: 37420217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]